SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Sanofi – ‘6-K’ for 6/17/15

On:  Wednesday, 6/17/15, at 10:34am ET   ·   For:  6/17/15   ·   Accession #:  1104659-15-45848   ·   File #:  1-31368

Previous ‘6-K’:  ‘6-K’ on / for 6/4/15   ·   Next:  ‘6-K’ on / for 7/29/15   ·   Latest:  ‘6-K’ on 4/25/24 for 3/31/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 6/17/15  Sanofi                            6-K         6/17/15    4:126K                                   Merrill Corp-MD/FA

Report of a Foreign Private Issuer   —   Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Report of a Foreign Private Issuer                  HTML     22K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     21K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     24K 
 4: EX-99.3     Miscellaneous Exhibit                               HTML     26K 


6-K   —   Report of a Foreign Private Issuer


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 


 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 


 

For the month of June 2015

 

Commission File Number: 001-31368

 

SANOFI

(Translation of registrant’s name into English)

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F x

Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes o

No x

 

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  82-        

 

 

 



 

In June 2015, Sanofi issued the statements attached hereto as Exhibit 99.1 to 99.3 which are incorporated herein by reference.

 

Exhibit List

 

Exhibit No.

 

Description

 

 

 

Exhibit 99.1

 

Press release dated June 9, 2015: FDA Advisory Committee Recommends Approval of Sanofi and Regeneron’s Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia

 

 

 

Exhibit 99.2

 

Press release dated June 8, 2015: Sanofi’s Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk

 

 

 

Exhibit 99.3

 

Press release dated June 6, 2015: Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Dated: June 17, 2015

 

SANOFI

 

 

 

 

 

 

 

By

/S/ John Felitti

 

 

Name:

John Felitti

 

 

Title:

Associate Vice President,

 

 

Corporate Law, Financial & Securities Law

 

3



 

Exhibit Index

 

Exhibit No.

 

Description

 

 

 

Exhibit 99.1

 

Press release dated June 9, 2015: FDA Advisory Committee Recommends Approval of Sanofi and Regeneron’s Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia

 

 

 

Exhibit 99.2

 

Press release dated June 8, 2015: Sanofi’s Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk

 

 

 

Exhibit 99.3

 

Press release dated June 6, 2015: Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes

 

4



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘6-K’ Filing    Date    Other Filings
Filed on / For Period End:6/17/15None on these Dates
6/9/15
6/8/15
6/6/15
 List all Filings 
Top
Filing Submission 0001104659-15-045848   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 26, 1:07:13.1pm ET